2023 non-GAAP EPS guidance is $3.25-3.45, based on $67-71M of revenue, down from $6.58 and $100.3B, respectively, in 2022 due to a sharp decline in COVID sales.
2023 guidance for PFE’s COVID sales: $13.5B for Comirnaty and $8B for Paxlovid, down from $37.8B and $18.9B, respectively, in 2022.
2023 organic-sales guidance excluding COVID products is YoY growth of 7-9%.
News 
Market Data 
Discover 
